Dulaglutide is a lab-made GLP-1 analog fused to the Fc portion of a modified human antibody. The result is a protein of about 63 kilodaltons with an elimination half-life of about 5 days, versus minutes for native GLP-1. FDA licensed it as Trulicity in 2014.
Quick answer: Dulaglutide is a GLP-1 receptor agonist built as a fusion protein. Dulaglutide is FDA-approved as the active ingredient in Trulicity. FDA licensed it as a biological product rather than approving it as a new drug, the route used for liraglutide and semaglutide. Approval covers the labeled product, not research material sold under the same name.
Vitrapep does not sell dulaglutide; this page is a reference summary of published research and regulatory information.
What is dulaglutide and how is it built?
Dulaglutide is a synthetic analog of glucagon-like peptide-1, a hormone the intestine releases after meals (see what GLP-1 is). Eli Lilly researchers developed it under the code LY2189265 [4].
The Trulicity label describes the molecule. Two identical chains are joined by disulfide bonds. In each chain, a small peptide linker connects a GLP-1 analog to the Fc portion of a modified human IgG4 heavy chain [1].
Lilly changed the GLP-1 region that interacts with DPP-4, the enzyme that inactivates native GLP-1. It also changed an area with a potential T-cell epitope. Fc changes target binding to high-affinity Fc receptors and half-antibody formation [1].
Glaesner and colleagues described the engineering in 2010. In cell assays, the fusion protein kept full GLP-1 receptor activity. Its half-life was 1.5 to 2 days in rats and cynomolgus monkeys [4]. These are animal and cell findings, not human data.
FDA regulations define a protein as an alpha amino acid polymer of defined sequence greater than 40 amino acids (21 CFR 600.3). Lilly submitted its application under section 351(a) of the Public Health Service Act, the pathway for biological products (approval letter). Vitrapep's peptide vs protein page explains the distinction.
What is dulaglutide and how is it built
| Property | Dulaglutide |
|---|---|
| Class | GLP-1 receptor agonist; Fc fusion protein [1] |
| Structure | Two identical disulfide-linked chains, each a GLP-1 analog, a small peptide linker and a modified human IgG4 Fc region [1] |
| Match to human GLP-1(7-37) | 90% homology in the GLP-1 analog portion [1] |
| Molecular weight | About 63 kilodaltons for the whole molecule [1] |
| Molecular formula | No PubChem compound record for the whole protein; PubChem lists the GLP-1 moiety (CID 171042928) as C149H221N37O49, 3314.6 g/mol [3] |
| Production | Mammalian (Chinese hamster ovary) cell culture [1] |
| Elimination half-life | About 5 days [1] |
| Breakdown | Presumed degraded into amino acids by general protein catabolism [1] |
| Developer | Eli Lilly and Company, code LY2189265 [2], [4] |
| US brand and first approval | Trulicity, September 18, 2014, under BLA 125469 [2] |
| First EU authorization | Trulicity, November 21, 2014 (EMA) |
How does dulaglutide work?
Dulaglutide activates the GLP-1 receptor, a cell-surface receptor coupled to adenylyl cyclase in pancreatic beta cells. Activation raises cyclic AMP inside the cell, which leads to insulin release that depends on blood glucose. Dulaglutide also lowers glucagon secretion and slows gastric emptying [1].
In people with type 2 diabetes, both first-phase and second-phase insulin secretion increased compared with placebo. The gastric emptying delay is largest at the start of treatment and then lessens [1].
Duration is the main difference from the natural hormone. Native GLP-1 lasts minutes because DPP-4 inactivates it and the body excretes it quickly [4]. Dulaglutide pairs an altered DPP-4 site with a much larger fusion structure. Liraglutide instead uses an attached fatty acid that binds albumin (see the liraglutide complete guide).
What is dulaglutide approved for?
Section 1 of the Trulicity label lists two uses. The first is improving glycemic control, with diet and exercise, in adults and children aged 10 and older with type 2 diabetes. The second is reducing major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or multiple risk factors [1].
The label lists no weight-management indication. Safety and effectiveness have not been established in children younger than 10 [1].
FDA approved the original application on September 18, 2014 [2]. The cardiovascular indication followed on February 21, 2020, based on REWIND (approval letter). The pediatric range followed on November 17, 2022 (approval letter). Vitrapep's list of FDA-approved peptide medicines explains how FDA separates peptides from proteins.
What did the key dulaglutide trials show?
REWIND (NCT01394952) ran at 371 sites in 24 countries, with a median baseline HbA1c of 7.2% [5]. The label notes that 62.8% had risk factors without established cardiovascular disease [1]. All-cause death occurred in 10.8% versus 12.0%, a difference that was not statistically significant [5]. In an exploratory analysis, a composite kidney outcome occurred in 17.1% versus 19.6%, with the clearest effect on new macroalbuminuria [6].
AWARD-6 (NCT01624259) tested dulaglutide against liraglutide in adults already taking metformin. Dulaglutide met the noninferiority margin for HbA1c. Nausea occurred in 20% versus 18% [7].
AWARD-PEDS (NCT02963766) found HbA1c below 7.0% in 51% of the pooled dulaglutide groups versus 14% on placebo. Body mass index did not differ between groups [8].
SURPASS-CVOT (NCT04255433) used dulaglutide as the active comparator for tirzepatide, noting it had been shown to reduce cardiovascular events [9]. Tirzepatide was noninferior, and superiority was not shown (see the tirzepatide complete guide).
What did the key dulaglutide trials show
| Trial | Population and size | Design and length | Primary result |
|---|---|---|---|
| REWIND, 2019 [5] | 9,901 adults aged 50 or older with type 2 diabetes and cardiovascular disease or risk factors | Double-blind, placebo-controlled; median follow-up 5.4 years | Major cardiovascular events 12.0% vs 13.4%; hazard ratio 0.88 (95% CI, 0.79 to 0.99) |
| AWARD-6, 2014 [7] | 599 adults with type 2 diabetes on metformin | Open-label, versus liraglutide; 26 weeks | HbA1c fell 1.42 vs 1.36 points; noninferior within a 0.4-point margin |
| AWARD-PEDS, 2022 [8] | 154 participants aged 10 to under 18 with type 2 diabetes | Double-blind, placebo-controlled for 26 weeks, then 26-week open-label extension | HbA1c rose 0.6 points on placebo; fell 0.6 and 0.9 points in the two dulaglutide groups |
| SURPASS-CVOT, 2025 [9] | 13,299 adults with type 2 diabetes and atherosclerotic cardiovascular disease | Double-blind, active comparator, versus tirzepatide | Major cardiovascular events 13.1% on dulaglutide vs 12.2% on tirzepatide; hazard ratio 0.92 (95.3% CI, 0.83 to 1.01) |
In SUSTAIN 7 (NCT02648204), an open-label trial funded by Novo Nordisk, 1,201 adults received semaglutide or dulaglutide for 40 weeks. HbA1c and body weight fell more with semaglutide at both paired dose levels [10].
What side effects does the Trulicity label list?
Boxed warning. In male and female rats, dulaglutide caused a dose-related and duration-dependent increase in thyroid C-cell tumors after lifetime exposure. It is unknown whether it causes such tumors in humans, including medullary thyroid carcinoma (MTC). It is contraindicated with a personal or family history of MTC or with MEN 2 [1].
One trial participant developed MTC; their calcitonin was about 8 times the upper limit of normal before treatment. REWIND recorded one case of C-cell hyperplasia with raised calcitonin [1].
Common reactions. The most common reactions, each in at least 5% of patients, are nausea, diarrhea, vomiting, abdominal pain and decreased appetite [1]. The pooled placebo-controlled adult data cover 1,670 adults exposed for a mean of 23.8 weeks.
What side effects does the Trulicity label list
| Adverse reaction | Placebo, % (N=568) | Dulaglutide, % (range across the two dose groups, N=836 and N=834) |
|---|---|---|
| Nausea | 5.3 | 12.4 to 21.1 |
| Diarrhea | 6.7 | 8.9 to 12.6 |
| Vomiting | 2.3 | 6.0 to 12.7 |
| Abdominal pain | 4.9 | 6.5 to 9.4 |
| Decreased appetite | 1.6 | 4.9 to 8.6 |
| Dyspepsia | 2.3 | 4.1 to 5.8 |
| Fatigue | 2.6 | 4.2 to 5.6 |
Source: Trulicity label, Table 1 [1]. Stopping because of gastrointestinal reactions occurred in 0.2% on placebo versus 1.3% and 3.5% in the two dose groups [1]. In REWIND, 47.4% on dulaglutide reported a gastrointestinal adverse event, versus 34.1% on placebo [5].
Warnings and precautions. The label warns of acute pancreatitis, including fatal hemorrhagic or necrotizing cases seen with GLP-1 receptor agonists. Confirmed pancreatitis occurred at 1.4 cases per 1,000 patient-years versus 0.88 with non-incretin comparators [1]. In REWIND, diabetic retinopathy complications occurred in 1.9% versus 1.5%, and serious acute cholecystitis in 0.5% versus 0.3% [1].
Other warnings cover hypoglycemia with insulin or sulfonylureas, acute kidney injury from volume depletion and serious hypersensitivity. Pulmonary aspiration during general anesthesia or deep sedation is also listed [1]. Mean heart rate rose 2 to 4 beats per minute in adults. Anti-drug antibodies developed in 1.6% of adults, with no identified clinically significant effect [1].
What changed for dulaglutide labels in 2026?
On March 12, 2026, FDA approved a Trulicity labeling change prompted by a class-wide safety signal on intestinal obstruction and fecal impaction. The postmarketing list now includes intestinal obstruction and severe constipation, including fecal impaction [12].
On November 9, 2026, FDA said all GLP-1 receptor agonist labels must warn of a potential increased risk of NAION, a rare optic nerve condition. Trulicity is on FDA's list. Across 126 randomized trials, NAION occurred at 6.4 cases per 100,000 person-years with GLP-1 receptor agonists versus 3.8 with comparators [13]. See Vitrapep's summary of FDA's GLP-1 eye-risk warning. The DailyMed label, posted August 10, 2026, did not yet include it on November 18, 2026 [1].
What is the regulatory status of dulaglutide?
Biologics license. Trulicity is licensed under BLA 125469 [2]. At approval, FDA required a risk strategy informing prescribers about thyroid C-cell tumors and pancreatitis. It also required postmarketing studies, including an MTC case registry of at least 15 years [11]. In December 2017, FDA said the risk strategy was no longer required (approval letter).
Compounding. FDA's 2018 guidance says biological products subject to licensure under section 351 are not eligible for the compounding exemptions in sections 503A and 503B [14]. Liraglutide and semaglutide medicines were instead approved as new drug applications (NDA 022341, NDA 209637).
Research-labeled products. FDA approval applies to Trulicity as made under its license. A research-use-only label does not make a product legal or safe for people. See research peptides and human-use risks and why research peptides have no dose.
Other countries and sport. The EMA overview describes EU use in adults and children from 10 years of age with type 2 diabetes (EMA). The WADA 2026 Prohibited List does not name dulaglutide or GLP-1 receptor agonists.
What is still unknown about dulaglutide?
The human relevance of the rat thyroid tumors has not been determined [1]. In children, the effect of anti-drug antibodies is unknown because they were uncommon [1]. The controlled pediatric period lasted 26 weeks [8]. The REWIND kidney findings come from an exploratory analysis [6]. FDA found no NAION mechanism in animal data [13].
Frequently asked questions
Is dulaglutide a peptide?
Its GLP-1 portion is a peptide, but the whole molecule is a fusion protein of about 63 kilodaltons. FDA licensed it as a biological product.
Is dulaglutide the same as Trulicity?
Dulaglutide is the active ingredient. Trulicity is the FDA-licensed product, with its own label and approved uses.
How is dulaglutide different from liraglutide and semaglutide?
All three activate the GLP-1 receptor. Dulaglutide is fused to an antibody Fc fragment, while liraglutide and semaglutide carry fatty acid chains.
Does dulaglutide have a boxed warning?
Yes. The Trulicity label warns about thyroid C-cell tumors in rats. Whether dulaglutide causes them in humans is unknown.
Is dulaglutide approved for weight loss?
No. The Trulicity label lists glycemic control in type 2 diabetes and cardiovascular risk reduction in some adults with type 2 diabetes.
Is research-grade dulaglutide FDA-approved?
No. FDA approval applies to Trulicity made under its biologics license. Material sold for laboratory research is not an approved medicine.
What to know now
- Dulaglutide is a GLP-1 analog fused to a modified IgG4 Fc fragment, with an elimination half-life of about 5 days.
- FDA licensed Trulicity as a biological product in 2014 and added a cardiovascular indication in 2020.
- REWIND showed fewer major cardiovascular events than placebo over a median of 5.4 years.
- In 2026, FDA added intestinal obstruction to the label and required a class-wide NAION warning.
What we’re watching
- NAION warning text appearing on the Trulicity label.
- Further SURPASS-CVOT analyses comparing tirzepatide with dulaglutide on heart and kidney outcomes.
- Any update to FDA's class-wide GLP-1 receptor agonist labeling.